Venetoclax
Cat. No.：YN270311
CAS No. ：1257044-40-8
| 产品名称: | Venetoclax |
| CAS No.: | 1257044-40-8 |
| Chemical Name: | 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide |
| Synonyms: | 维奈妥拉; ABT-199; GDC-0199 |
| 分子量: | 868.44 |
| 分子式: | C₄₅H₅₀ClN₇O₇S |
| SMILES: | O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Venetoclax (ABT-199; GDC-0199) 是一种高效，有选择性和口服有效的Bcl-2抑制剂，Ki小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。 |
| IC50和靶点: | [{name:"Bcl-2:0.01 nM (Ki)"},{name: "Bcl-xL:48 nM (Ki)"},{name: "Bcl-W:245 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Davids, M.S., and Letai, A.ABT-199: A new hope for selective BCL-2 inhibitionCancer Cell23(2),139-141(2013)
Souers, A.J., Leverson, J.D., Boghaert, E.R., et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNat. Med.19(2),202-208(2013)
Tamaki, H., Harashima, N., Hiraki, M., et al.Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibitionOncotarget,(2014)
